Vaxart Inc Stock Performance
| VXRT Stock | USD 0.70 0.05 7.69% |
Vaxart holds a performance score of 13 on a scale of zero to a hundred. The entity has a beta of 0.46, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Vaxart's returns are expected to increase less than the market. However, during the bear market, the loss of holding Vaxart is expected to be smaller as well. Use Vaxart Inc maximum drawdown, skewness, as well as the relationship between the Skewness and day typical price , to analyze future returns on Vaxart Inc.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Vaxart Inc are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively abnormal basic indicators, Vaxart unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:11 | Dividend Date 2018-02-14 | Ex Dividend Date 2012-11-09 | Last Split Date 2018-02-14 |
1 | Best data tools to analyze Vaxart Inc. stock - Trade Exit Summary Low Risk High Win Rate Picks - newser.com | 10/28/2025 |
2 | A Look at Vaxarts Upcoming Earnings Report | 11/12/2025 |
3 | Vaxart extends cash runway into Q2 2027 with Dynavax partnership and targets 2026 data readouts | 11/14/2025 |
4 | Acquisition by Heron Elaine J of 23217 shares of Vaxart at 0.393 subject to Rule 16b-3 | 11/17/2025 |
5 | Acquisition by Michael Finney of 44224 shares of Vaxart at 0.74 subject to Rule 16b-3 | 11/21/2025 |
6 | Disposition of 54153 shares by Steven Lo of Vaxart at 0.37 subject to Rule 16b-3 | 12/04/2025 |
7 | Vaxart Stock Price Passes Below 200 Day Moving Average - Heres Why - MarketBeat | 12/17/2025 |
8 | Vaxart to Relocate Headquarters Amid Lease Termination - The Globe and Mail | 12/30/2025 |
9 | Vaxart to Participate in the Global BioInnovation Forum on January 13, 2026 | 01/08/2026 |
10 | Vaxart Publishes Positive Data for its Oral Bivalent Norovirus Candidate in Lactating Women and Their Infants | 01/15/2026 |
| Begin Period Cash Flow | 34.8 M | |
| Total Cashflows From Investing Activities | -21.3 M |
Vaxart Relative Risk vs. Return Landscape
If you would invest 36.00 in Vaxart Inc on October 20, 2025 and sell it today you would earn a total of 34.00 from holding Vaxart Inc or generate 94.44% return on investment over 90 days. Vaxart Inc is currently generating 1.4154% in daily expected returns and assumes 8.5649% risk (volatility on return distribution) over the 90 days horizon. In different words, 76% of stocks are less volatile than Vaxart, and 72% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Vaxart Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vaxart's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Vaxart Inc, and traders can use it to determine the average amount a Vaxart's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1653
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | VXRT | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Vaxart is performing at about 13% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Vaxart by adding it to a well-diversified portfolio.
Vaxart Fundamentals Growth
Vaxart Stock prices reflect investors' perceptions of the future prospects and financial health of Vaxart, and Vaxart fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vaxart Stock performance.
| Return On Equity | -1.07 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (0.34) % | ||||
| Operating Margin | (0.11) % | ||||
| Current Valuation | 155.1 M | ||||
| Shares Outstanding | 240.06 M | ||||
| Price To Book | 6.30 X | ||||
| Price To Sales | 1.13 X | ||||
| Revenue | 28.7 M | ||||
| Gross Profit | (30.88 M) | ||||
| EBITDA | (54.87 M) | ||||
| Net Income | (66.95 M) | ||||
| Cash And Equivalents | 129.55 M | ||||
| Cash Per Share | 1.02 X | ||||
| Total Debt | 23.28 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 8.65 X | ||||
| Book Value Per Share | 0.12 X | ||||
| Cash Flow From Operations | (44.76 M) | ||||
| Earnings Per Share | (0.22) X | ||||
| Market Capitalization | 168.04 M | ||||
| Total Asset | 166.39 M | ||||
| Retained Earnings | (476.52 M) | ||||
| Working Capital | (22.62 M) | ||||
About Vaxart Performance
Assessing Vaxart's fundamental ratios provides investors with valuable insights into Vaxart's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Vaxart is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 100.19 | 53.42 | |
| Return On Tangible Assets | (0.49) | (0.51) | |
| Return On Capital Employed | (1.01) | (0.96) | |
| Return On Assets | (0.46) | (0.44) | |
| Return On Equity | (1.31) | (1.24) |
Things to note about Vaxart Inc performance evaluation
Checking the ongoing alerts about Vaxart for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Vaxart Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Vaxart Inc is way too risky over 90 days horizon | |
| Vaxart Inc has some characteristics of a very speculative penny stock | |
| Vaxart Inc appears to be risky and price may revert if volatility continues | |
| Vaxart Inc has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 28.7 M. Net Loss for the year was (66.95 M) with loss before overhead, payroll, taxes, and interest of (30.88 M). | |
| Vaxart Inc currently holds about 129.55 M in cash with (44.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Vaxart Inc has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Canaccord Genuity lowers Adicet Bio stock price target to 18 from 128 - Investing.com |
- Analyzing Vaxart's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vaxart's stock is overvalued or undervalued compared to its peers.
- Examining Vaxart's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Vaxart's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vaxart's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Vaxart's stock. These opinions can provide insight into Vaxart's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Vaxart Stock Analysis
When running Vaxart's price analysis, check to measure Vaxart's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxart is operating at the current time. Most of Vaxart's value examination focuses on studying past and present price action to predict the probability of Vaxart's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxart's price. Additionally, you may evaluate how the addition of Vaxart to your portfolios can decrease your overall portfolio volatility.